Drug Trial Radar · NCT05280314
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 21, 2023
Primary completion
Apr 30, 2025
Study completion Jan 2027
Sponsor
- Lead sponsor
- IO BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Theradex; Almac; Merck Sharp & Dohme LLC
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Conditions
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
Interventions
IO102-IO103Drug
IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
Pembrolizumab KEYTRUDA®Drug
Pembrolizumab KEYTRUDA® administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major pathologic responseTime frame: Observed in the resected tumor tissue after neoadjuvant treatment at surgery
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
Yale
New Haven, Connecticut · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Massey Cancer Center
Richmond, Virginia · Recruiting
Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital
Sydney, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Copenhagen University Hospital Herlev
Copenhagen, Denmark · Recruiting
CHRU Lille
Lille, France · Recruiting
Hôpital Ambroise-Paré
Paris, France · Recruiting
Institut Gustave Roussy
Paris, France · Recruiting
Universitätsklinikum Essen & Research Alliance Ruhr
Essen, Germany · Recruiting
Universität Heidelberg, Medizinische Fakultät
Heidelberg, Germany · Recruiting
Hospital Universitario Quirón Dexeus
Barcelona, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Recruiting
Hospital Clínico Universitario de Valencia -INCLIVA
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.